Unraveling the Potential of C10orf95: A novel protein Target for Cancer Treatment

Target Name: C10orf95

NCBI ID: G79946

C10orf95

Other Name(s): Uncharacterized protein C10orf95 | Chromosome 10 open reading frame 95 | CJ095_HUMAN | chromosome 10 open reading frame 95

Unraveling the Potential of C10orf95: A novel protein Target for Cancer Treatment

Cancer is one of the leading causes of human death worldwide, with over 80% of all deaths due to cancer. The development of new treatments is crucial for improving survival rates and managing the burden of cancer. One promising approach to combat cancer is the identification of novel protein targets, such as C10orf95, which can be targeted by drugs to enhance their effectiveness. In this article, we will explore the scientific literature on C10orf95 and its potential as a drug target or biomarker for cancer treatment.

C10orf95: A Unique Protein

C10orf95 is a 193-kDa protein that is expressed in various tissues, including skeletal muscles, heart, liver, and brain. It is a member of the TOW family, which includes proteins involved in cell signaling, DNA replication, and apoptosis. C10orf95 has unique features that make it an attractive candidate for drug targeting.

One of its defining features is its potential to interact with multiple protein partners, including transcription factors, DNA-binding proteins, and tyrosine kinases. This interactivity suggests that C10orf95 could play a significant role in regulating gene expression and cellular processes, making it a potential drug target. Additionally, C10orf95 has been shown to have pro-inflammatory and pro-tumorigenic properties, which may make it an attractive target for cancer treatment.

Cancer-Related Functionality

Several studies have demonstrated the involvement of C10orf95 in various cancer-related processes. For instance, overexpression of C10orf95 has been shown to promote the growth and metastasis of various cancer types, including breast, lung, and colorectal cancer. This suggests that C10orf95 may contribute to the development and progression of cancer.

In addition to its oncogenic properties, C10orf95 has also been shown to have pro-inflammatory effects. The production of pro-inflammatory cytokines, such as TNF-伪 and IL-6, is a well-established hallmark of cancer-induced inflammation. C10orf95 has been shown to induce the production of these cytokines, which may contribute to the immune evasion tactics that cancer cells employ to evade the immune system's defenses.

Drug Targeting Strategies

C10orf95's unique properties make it an attractive target for drug development. One approach to targeting C10orf95 is to use small molecules, such as drugs that can modulate its activity or interactions with other proteins. Additionally, protein kinases, such as FAK and IRAK4, have been shown to be involved in the regulation of C10orf95 activity. Therefore, targeting these kinases may be an effective way to modulate C10orf95's activity.

Another potential strategy for targeting C10orf95 is to use antibodies that can specifically recognize and bind to its protein target. The development of monoclonal antibodies (MCAs) targeting C10orf95 is an promising approach that may provide a more targeted and effective way to treat cancer.

Cancer Biomarkers

C10orf95 may also be used as a biomarker for cancer diagnosis and monitoring. The expression of C10orf95 has been shown to be elevated in various cancer types, including breast, lung, and colorectal cancer. Additionally, the production of pro-inflammatory cytokines, such as TNF-伪 and IL-6, has been shown to be increased in cancer cells. Therefore, the levels of C10orf95 and its associated cytokines could be used as biomarkers for cancer diagnosis and monitoring.

Conclusion

In conclusion, C10orf95 is a unique protein that has been shown to have various cancer-related functions. Its potential as a drug target or biomarker makes it an attractive candidate for cancer treatment. The development of new treatments for cancer depends on the continued research and identification of novel protein targets. As the field of cancer research continues to evolve, we can expect to see new approaches to targeting C10orf95 and other protein targets emerge.

Protein Name: Chromosome 10 Open Reading Frame 95

The "C10orf95 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C10orf95 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets